To decrease the incidence of chemotherapy-induced myelosuppression in patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen

For extensive-stage small cell lung cancer (ES-SCLC)

MYELOPROTECTION: PROACTIVELY HELP PROTECT MULTIPLE BLOOD CELL LINEAGES

PROTECTING HSPCs
Unique Cell Cycle Action

COSELA Helps Protect the Source

  • When COSELA™ (trilaciclib) is given prior to chemotherapy, it transiently arrests hematopoietic stem and progenitor cells (HSPCs), the source of blood cell lineages, in the G1 phase of the cell cycle to help protect them during chemotherapy
A blood cell lineage graph illustrating how when COSELA is given prior to chemotherapy, it can help protect more of a patient’s HSPCs

available interventions attempt to address individual cell lines after the effects of chemotherapy1

  • Myeloprotection strategy: When given prior to chemotherapy, COSELA transiently arrests HSPCs in the G1 phase of the cell cycle
  • Proactive myeloprotection: COSELA offers healthcare providers a new mechanism to address myelosuppression early in the blood cell development process—before chemotherapy affects HSPCs

WHEN COSELA IS GIVEN intravenously PRIOR TO CHEMOTHERAPY, IT has a unique effect on the HSPC cell cycle to HELP provide protection

COSELA™ (trilaciclib) provides transient inhibition of the CDK4/6 pathway when given prior to chemotherapy (on days chemotherapy is administered)

  • Proliferating HSPCs are susceptible to chemotherapy damage, resulting in myelosuppression; their proliferation is dependent on cyclin-dependent kinase (CDK) 4 and 6 activity
  • COSELA temporarily arrests HSPCs in the G1 phase of the cell cycle
  • This temporary arrest has been shown to help protect HSPCs from chemotherapy-induced damage
    • After removal of COSELA, HSPCs are able to resume activity to help maintain bone marrow function2*

*Effect demonstrated in in vivo preclinical studies.

Graphic illustrating how COSELA transiently arrests HSPCs in the G1 phase of the cell cycleG1MG2SCDK4/6TRANSIENTARRESTCDK2CDK2CDK1pRbRb

INDICATION: COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

WATCH THE COSELA MOA VIDEO

COSELA helps protect hematopoietic stem and progenitor cells (HSPCs), the source of multiple blood cell lineages. See the mechanism of action (MOA) of COSELA.

Watch the MOA Video